Recurrent mutations in core splicing factors have been reported in several clonal disorders, including cancers. Mutations in SF3B1, a component of the U2 splicing complex, are the most common. SF3B1 mutations are associated with aberrant pre-mRNA splicing using cryptic 3′ splice sites (3′SSs), but the mechanism of their selection is not clear. To understand how cryptic 3′SSs are selected, we performed comprehensive analysis of transcriptome-wide changes to splicing and gene expression associated with SF3B1 mutations in patient samples as well as an experimental model of inducible expression. Hundreds of cryptic 3′SS were detectable across the genome in cells expressing mutant SF3B1. These 3′SS are typically sequestered within RNA secondary structures and poorly accessible compared with their corresponding canonical 3′SS. We hypothesized that these cryptic 3′SS are inaccessible during normal splicing catalysis and that this constraint is overcome in spliceosomes containing mutant SF3B1. This model of secondary structure-dependent selection of cryptic 3′SS was found across multiple clonal processes associated with SF3B1 mutations (myelodysplastic syndrome and chronic lymphocytic leukemia). We validated our model predictions in mini-gene splicing assays. Additionally, we found deregulated expression of proteins with relevant functions in splicing factor-related diseases both in association with aberrant splicing and without corresponding splicing changes. Our results show that SF3B1 mutations are associated with a distinct splicing program shared across multiple clonal processes and define a biochemical mechanism for altered 3′SS choice.
INTRODUCTION
Whole-genome sequencing has recently identified recurrent mutations in the core splicing machinery of several acquired clonal diseases, including cancers. 1 Splicing mutations are most common in myelodysplastic syndrome (MDS), a group of clonal myeloid neoplasms 2, 3 of the blood characterized by progressive bone marrow failure and genomic instability resulting in leukemic transformation. [4] [5] [6] Most of these mutations are restricted to four proteins (SF3B1, U2AF1, SRSF2 and ZRSR2), of which SF3B1 mutations are the most common. Splicing factor mutations have also been reported in other neoplasms, including chronic lymphocytic leukemia (CLL) 7 and uveal melanoma, 8 suggesting common underlying mechanisms of clonal evolution in splicing factor mutations. Although it is logical to suspect the aberrant splicing of key transcripts are directly responsible for clonal evolution and hematopoietic dysplasia, the details of such a mechanism are not fully known. SF3B1 is a component of the multi-protein complex SF3B and is thought to be important in stabilizing the base pairing of U2 snRNA to the branch point (BP). 9 All disease-associated mutations of SF3B1 are within its 22 HEAT domains that form rod-like helical structures in its carboxyl-terminal region. SF3B1-mutant MDS is also associated with a specific phenotype called 'ring sideroblasts', which are maturing red cell precursors with a ring of iron-laden mitochondria around their nuclei. 4 Recently, multiple groups have described usage of novel or 'cryptic' 3′ splice sites (3′SSs) in patient samples with SF3B1 mutations. 10, 11 These aberrantly spliced transcripts may have loss-or gain-of-function physiology, thus providing a link between SF3B1 mutations and disease biology. Two mechanisms have been recently proposed to understand this link. Based on computational modeling of the distance distribution of cryptic 3′SS in relation to their corresponding canonical 3′SS, DeBoever et al. 10 proposed that mutant SF3B1 is able to recognize cryptic 3′SS located proximal to the sterically protected region downstream of the BP, without actually changing the BP choice itself. Darman et al.
11 proposed a different model by which the SF3B1-mutants have altered BP selectivity that lead to altered 3′SS choice. In this manuscript, we provide evidence that these cryptic 3′SSs are rendered inaccessible owing to their presence within RNA secondary structures, while they are recognized by mutant SF3B1-containing spliceosomes. These computational models were verified in mini-gene splicing experiments. Our results provide a potential biochemical mechanism for altered 3′SS choice in SF3B1-mutant-expressing cells and could ultimately provide insight into the mechanisms of mutant SF3B1-associated MDS.
RESULTS
Aberrant splicing of transcripts using cryptic 3′SSs in cells expressing mutant SF3B1 Our analysis of mutant SF3B1-associated RNA splicing utilized two systems. Given that native human SF3B1 open reading frame is toxic to Escherichia coli, 12 we synthesized a codon-optimized construct that allowed easy cloning (Materials and Methods). For transgenic expression of this construct, we developed an inducible lentiviral expression system with the hematopoietic cell line K562 and pInducer vector system by which we could limit the transgene expression levels close to that of the endogenous protein (Supplementary Figure S1) . Cells induced to express SF3B1 wildtype or K700E are referred to as SF3B1 WT and SF3B1 K700E , respectively. Paired-end RNA-Sequencing (RNA-Seq) was performed on total RNA depleted of ribosomal RNA (rRNA) using Illumina HiSeq2000 resulting in approximately 82 × 10 6 reads per library (detailed statistics shown in Supplementary Tables S1 and S2). rRNA depletion was employed instead of polyA selection to avoid loss of non-adenylated intermediaries. Mapping of paired-end RNA-Seq to the genome (hg19) resulted in a total of 182 190 splice junctions (SJ) from SF3B1 WT Table S3 ) for downstream analysis. Similar analyses on patient samples (bone marrow-derived CD34+ cells from 8 SF3B1-mutant MDS patients (variant allele frequency of 46-52% and 5 healthy controls) are available from the Gene Expression Omnibus (GEO) database (GSE63569). 13 We found 430 052 SJ in this comparison of which 219 297 were novel.
We analyzed novel SJ to determine novel or 'cryptic' 3′SSs (defined as SJ associated with annotated 5′SS but novel 3′SS). In all, 741 and 859 cryptic 3′SSs were found in SF3B1 K700E and MDS patient samples, respectively (Supplementary File S1). These cryptic 3′SSs were found to be widely distributed in their distance from corresponding canonical 3′SSs (60% were upstream and 40% were downstream in SF3B1 K700E ; 61% and 39%, respectively, in the MDS patient samples). Importantly, we noted an enrichment of cryptic 3′SSs immediately upstream (10-35 nucleotide or nt) of the canonical 3′SSs (Figure 1a ), but no such pattern was evident in the downstream cryptic 3′SSs (Supplementary Figure S2A) . When the sequence motif in region upstream of cryptic 3′SSs was compared with canonical 3′SSs, the polypyrimidine tract (PPT) was noted to be interrupted with adenosines (Figure 1b Cryptic 3′SSs are less accessible compared with canonical counterparts Although our results discussed above and previous reports 10, 11, 14 show that sequence upstream of cryptic and canonical 3′SSs differ (PPTs enriched in adenosines for the former), this does not provide a direct mechanism for their selection. We hence considered other attributes of cryptic 3′SSs, including secondary structure. Secondary structure of nascent transcripts is a well-known determinant of splicing outcome. 15 Effect of secondary structures have been demonstrated on the choice of 5′SSs, 3′SSs and BP across multiple species. [16] [17] [18] In eukaryotes, 3′SS selection is thought to involve 5′ → 3′ linear scanning of the sequence downstream from the BP, and the first AG downstream is selected. 19 However, AGs are skipped when they are too close to the BP (presumably as these are sterically protected) or if they are inaccessible within hairpin structures. 20 The enrichment of cryptic 3′SSs immediately upstream of canonical 3′SSs prompted us to check if they are hidden within secondary structures and hence not accessible normally during the 5′ → 3′ scanning in the second step of splicing. We first investigated the sequence around several candidate cryptic 3′SSs for the presence of secondary structures using Mfold. 21 As shown by representative examples in Figure 1c and Supplementary Figure S3 , cryptic 3′SSs are typically located within well-defined secondary structures that exclude their corresponding canonical 3′SSs. This prompted us to test our hypothesis across the genome. Descriptive examples of cryptic 3′SS usage in SF3B1 K700E are shown in Figure 1d . As nascent pre-mRNA folds co-transcriptionally, multiple dynamically forming secondary structures are possible, 22, 23 by which the AG dinucleotide of a particular 3′SS can base-pair and hence be rendered inaccessible. One strategy to account for these scenarios is to include base-pairing probability (or corresponding accessibility of 3′SSs) across multiple structures, including optimal and suboptimal. 24, 25 Comparison of accessibility between cryptic and canonical 3′SSs would be most meaningful in instances where they are both associated with a common BP. If our hypothesis were true, cryptic 3′SSs would be less accessible than canonical during 5′ → 3′ scanning from the BP. However, BP in vertebrates are highly degenerate and hence cannot be computationally determined precisely for all 3′SSs. 26 To computationally test our model, we hence identified those cryptic 3′SSs that were reliably predicted to share a BP with their corresponding canonical 3′SS using SVM_BP, a tool to predict BP in mammalian introns. 27 A total of 275 such cryptic 3′SS in the patient data set and 97 from SF3B1 K700E were identified (placed upstream of their canonical 3′SSs). Also, 59 and 109 such cryptic 3′SSs with shared predicted BP were identified to be downstream of the canonical 3′SSs in the patient sample and K562 data sets, respectively. To compare relative accessibility, a sequence stretch downstream of the shared BP including the cryptic and canonical 3′SSs and a further 15 nt downstream was selected ( Figure 2a ) and accessibility of cryptic and canonical 3′SSs was calculated using RNAfold. 28 Accessibility of cryptic 3′SSs was significantly reduced compared with their corresponding canonical counterparts (Figure 2b , Wilcoxon signed-rank test; P = 2.20E-16 for MDS patients and o 6.629E-08 for SF3B1 K700E ). We performed similar analysis with 214 cryptic 3′SSs from an independent data set of CLL patients, 10 which also showed a similar pattern of reduced accessibility (P = 1.28E-10). Importantly, similar results were obtained for cryptic 3′SSs that were located downstream of canonical 3′SSs with shared predicted BP (Supplementary Figure S4A) . These analyses strongly support the hypothesis that cryptic 3′SSs are protected within secondary structures in normal conditions, an effect that is seen regardless of whether cryptic 3′SSs are located upstream or downstream of canonical counterparts, as long as they are in proximity.
Direct comparison of accessibility is not feasible for those cryptic/canonical pairs that do not share a BP (either because they are far from each other and hence unlikely to share a BP or no reliable BP predication could be made). Accessibilities calculated on independent sequence windows (starting from their respective BP to 15 nt downstream of 3'SSs) are not expected to be different given that these splice sites are not in competition during the 5′ → 3′ scanning of the spliceosome. Consistent with this hypothesis, we found that their relative accessibilities were not different ( Supplementary Figures S4B and C) . Taken together, our results show that accessibility of cryptic 3′SSs that share a BP with their canonical 3′SSs is significantly lower than the canonical 3′ SSs. Although the model can be extended to all cryptic 3′SSs regardless of their distance from canonical 3′SSs (detailed in Discussion section), rigorous computational validation is only possible in this subset. Given that core splice motifs critical to normal function are typically highly conserved, we also investigated whether cryptic 3′SSs are also conserved using PhyloP conservation score for 100 vertebrates 29 ( Figure 2c ). Although canonical 3′SSs showed high levels of conservation, cryptic 3′SSs were poorly conserved across vertebrates, suggesting that these sites do not have an evolutionarily preserved function.
To validate our computational model of 3′SS accessibility, we performed splicing assays using mini-gene constructs with different intronic inserts where splice forms from cryptic and canonical 3′SSs could be differentiated by size resolution on agarose gel (Figures 3a and b) . A control intron (91 bp long, based on a mouse immunoglobulin heavy chain 30 ) with canonical splice donor and acceptor sites was cloned between chicken Troponin T exonic elements (RG6 vector) 31 to create the control mini-gene (designated as I). Two additional constructs were designed: minigene II with a 12-bp hairpin upstream of the canonical 3′SS and mini-gene III that lacked the 5′ side of the hairpin (no secondary structure is hence predicted to form). A cryptic AG was placed . Bands in the gel pictures are marked with gray and black arrows, which correspond to isoforms associated with the cryptic and canonical 3′SSs, respectively. results are thus in agreement with the hypothesis that upstream AGs typically not accessible within secondary structures are rendered accessible in SF3B1 K700E -expressing cells.
SF3B1
K700E expression alters splicing pattern of hundreds of genes, including those associated with cancer Cryptic 3′SSs as described above were determined by analysis of SJ. To determine alternative splicing events (skipped exon; SE, mutually exclusive exon; MXE, alternative 5′ splice site; A5SS, alternative 3′ splice site; A3SS and retained intron; RI), we implemented rMATS, an algorithm that takes into consideration exon coverage in addition to SJ reads. From a comprehensive set of transcript annotations (assembled with Cufflinks 32 ), we extracted and quantified the five common splicing events ( Figure 4a and Supplementary Figures S5A and B) . A total of 10 435 significant alternatively spliced events spread across 4742 annotated genes were detected in SF3B1 WT (Figure 4b ). The preponderance of SE as the predominant differentially spliced event (in excess of alternate 3′ splice site) is seemingly contrary to the primary role of SF3B1 in 3′SS selection. Both technical and biological reasons could explain this discrepancy: (1) Skipped exons are the most common alternative splicing event annotated in human transcriptome. 33 Given that rMATS analysis is biased toward existing annotations, this may result in a higher proportion of SE compared with other events. (2) Skipped exons may indirectly result from altered activity of other splicing regulators (such as PTB, HNRP and SR proteins), which are differentially spliced in our data sets (Supplementary Files S2 and S3). Interestingly, a similar study of splicing changes induced by U2AF1 mutants also showed a preponderance of SE. Wilcox signed-rank P-value denoted as 'P' defines the statistical significance of the difference in accessibilities between 'n' number of canonical and cryptic 3′SSs. Accessibility of canonical and cryptic 3′SSs was determined in the sequence region between BP (after excluding 8 nucleotides downstream of BP 'A') and 3′SS plus 15 nucleotides downstream (defined as BS-3′SS). The accessibilities were calculated in 16 windows (that is, BS-3′SS+0, 1, 2,….15) using RNAfold and averaged. (c) Base wise conservation around canonical and cryptic 3′SSs analyzed in panel (b). Shown are the average conservation scores (− log P-values) from 100 vertebrates (phyloP100way) in the three data sets MDS, K562 and CLL.
The ΔPSI (difference between 'percentage spliced in' of SF3B1 WT and SF3B1 K700E ) for all significant events have a wide distribution (Figure 4c ). When comparing K562-SF3B1
WT and SF3B1 K700E , 39% of events had ΔPSI o 10% (or |0.1|) while the corresponding proportion was 75% in patient samples, suggesting that the demonstrable change in splicing isoform was modest for most transcripts. A list of genes with the 50 highest ΔPSI values is given in Table 1 . We performed unsupervised cluster analysis of inclusion level of the predominant splicing event, SE with at least ΔPSI of 10% (243 events in SF3B1
WT vs SF3B1 K700E and 510 events in Healthy vs MDS). In both comparisons, samples clustered along their SF3B1 mutational status confirming that the splicing events reproducibly linked to the expression of mutant SF3B1 (Supplementary Figures S5C and D) . Approximately 40% (953 of the 2356) differentially spliced genes in SF3B1
WT vs SF3B1 K700E were represented in the patient data sets, although only 6% of the specific events themselves were shared (Supplementary Figures S5E and F) . The low concordance of specific splice events may be explained by the distinct transcriptomes of K562 cells and CD34-selected cells, as well as by differences between induced vs stable expression systems. Nonetheless, those altered splicing events shared between the patient samples and our experimental model may be highly conserved across different cell types and, as such, may be important for pathogenesis of disease related to recurrent HEAT domain mutations in SF3B1. Several genes with relevance to cancer and MDS biology were noted to undergo alternative splicing (Supplementary Files S2 and S3). However, most including EZH2, NRAS and GATA1 contained events with low ΔPSI values. We experimentally validated differentially spliced events in four genes relevant to cancer and MDS biology (BCL2L12, 35 (Figure 4d ).
K700E expression leads to differential expression of genes both directly and indirectly To investigate how these differentially spliced genes may contribute to MDS pathophysiology, we performed pathway analysis (Ingenuity Pathway Analysis) and determined the biological pathways enriched in these data sets (Figure 5a and Supplementary File S4). Both the data sets showed significant enrichment for pathways directing functions, including protein quality control, mitochondrial function, cell death and proliferation and regulation of gene expression. One of these genes, UBE2I encodes the SUMO E2 ligase Ubc9 39 and was found to be differentially spliced (SE in the 5′ untranslated region (UTR) that results in isoforms that differ in 5′ UTR) (Supplementary Files S2 and S3 and Figure 5b ). Although the total transcript level was not different (Figure 5c ), protein levels in SF3B1 K700E cells were found to be lower than SF3B1
WT (Figure 5d ), suggesting that the mechanism of differential gene expression may be posttranscriptional (regulatory elements in 5′ UTR have been reported to regulate rate of translation 40 ). SLC25A37 or Mitoferrin 1 is a critical mitochondrial iron transporter, the loss of which results in severe anemia in experimental models. 41 Mitoferrin 1 has been reported to be both alternatively spliced and differentially expressed in SF3B1-mutant MDS. 13, 42 We noted Mitoferrin 1 demonstrated differential splicing in SF3B1 K700E as well as in MDS patient samples, albeit with only small differences in splicing ratio (Figures 5e and f) In mini-gene I, canonical 5′SS and 3′SS use will result in a 122 bp amplicons. In mini-genes II and III, use of the downstream AG will also result in a 122-bp product, but if the upstream AG is used, the product is 136 bp (additional 14 bp long). Based on our hypothesis, upstream AG of mini-gene II is not favored in normal conditions as it is sequestered within the hairpin, hence downstream AG will be used preferentially. In mutant SF3B1-containing spliceosomes, we hypothesize that this sequestration can be overcome and hence the upstream AG will be favored (resulting in the 136 bp product). In mini-gene III, the upstream AG is favored (in both SF3B1
WT and SF3B1 K700E spliceosomes) given there is no hairpin structure. (c) Agarose gel electrophoresis of amplicons from cDNA amplified with nested primers. Each construct was co-transfected with either the SF3B1 WT or the SF3B1 K700E construct. A 122-bp product is formed with the use of canonical 3′SS; the product is 136 bp when the upstream cryptic 3′SS is used. Mini-gene II co-transfected with SF3B1
WT predominantly uses the canonical AG with some use of the upstream cryptic AG. When SF3B1 K700E is transfected, the upstream cryptic 3′ AG is almost exclusively used. Both SF3B1 WT and SF3B1 K700E preferentially use the upstream AG in mini-gene III.
antibody against the human epitope). Mitoferrin 1 is known to be regulated posttranslationally, 43 hence the higher transcript levels may represent a compensatory increase to its degradation.
A small set of genes was found differentially expressed in SF3B1 K700E cells compared with SF3B1 WT cells (Table 2 and Supplementary File S5). This list included several genes previously known to be important in MDS and cancer biology, including EGR1, (an immediate early transcription factor, the loss of which can lead to HSC expansion 44 ) and DLK1 (a member of the EGF-like family of proteins with both transmembrane and secreted forms 45 known to be downregulated in the RARS subtype of MDS 46 ). Differential transcript and protein levels for EGR1 and DLK1 are shown in Supplementary Figure S6 . Given that they are not alternatively spliced, it is likely that their differential expression is indirectly related to mutant SF3B1 expression. To discount mutant-specific and cell-line-specific effects, our results were also confirmed for other HEAT domain mutants reported in MDS (SF3B1 K666N and SF3B1 K666R ) and in the murine MEL erythroleukemia cell line (Supplementary Figures S7 and S8) .
Elimination of aberrantly spliced isoforms by nonsensemediated decay (NMD) surveillance has been invoked as a mechanism by which splicing mutations may lead to changes in protein expression. 47 Potential for transcript isoforms to trigger NMD can be computationally predicted (premature termination codon, long 3′ UTR, SJ450 nt downstream of the stop codon).
However, for NMD to be invoked as a potential mechanism for differential gene expression, a change in transcript abundance at steady state is expected. Among the few differentially expressed genes between SF3B1
WT and SF3B1 K700E cells (Table 2) , only two (Mitoferrin 1 and HDAC7) show known NMD-triggering features described above (Supplementary Files S2 and S3). We determined whether inhibition of NMD (by treatment with cycloheximide 48 ) would increase the relative abundance of Mitoferrin 1 isoforms predicted to be NMD targets. We did not observe a significant change in these isoform levels assayed by quantitative reverse transcription-PCR (Supplementary Figure S9) , suggesting that mechanisms other than NMD may have a role in differential expression of genes, including Mitoferrin 1, in SF3B1 K700E cells.
DISCUSSION
In this manuscript, we propose a new model for splicing changes associated with recurrent mutations in the HEAT domains of SF3B1 described in multiple clonal processes, including MDS, CLL, uveal melanoma and breast cancer. Previous studies have described changes in 3′SS selection in cells that express mutant SF3B1. 10, 11 Our results are in general agreement with these reports with regards to the distribution of cryptic 3′SSs and associated weak PPT. In addition, our analysis shows that cryptic 3′SS used by SF3B1 K700E are typically sequestered within secondary structures WT or SF3B1 K700E cells and analyzed by isoform-specific quantitative reverse transcription-PCR are shown to the right (P o0.05). Three of the shown genes (BOLA3, BCL2L12 and DROSHA) have SE as their primary altered splicing event while IMMT features an alternative 3′ splice site (A3SS). In the rMATS analysis, difference in percentage of spliced in (ΔPSI)40 refers to higher level of exon inclusion (or longer isoform) in control sample relative to mutant, whereas ΔPSI o0 to the inclusion level in the opposite direction. Here exon inclusion refers to the longer isoform of the events, SE, RI, A5SS and A3SS, whereas for MXE, inclusion of first mutually exclusive exon refers to the longer isoform.
and not accessible to nucleophilic attack in wild-type cells. SF3B1 K700E expression overcomes this constraint rendering them accessible ( Figure 6 ).
Three recent studies have proposed divergent mechanistic models to explain how mutant SF3B1 expression leads to cryptic 3′SS usage. The first by DeBoever et al. 10 proposed that mutant SF3B1 is able to recognize cryptic 3′SSs by overcoming the usual steric hindrance in a region immediately downstream of the BP. Specifically, they discounted altered BP selection as the cause for cryptic 3′SS selection. Two limitations for the model were: (1) it could not explain cryptic 3′SSs that fell farther away from this sterically protected region; and (2) the model was not supported with direct experimental validation. A second model based on multiple SF3B1-mutant cancer samples 11 (and a more recent similar study in SF3B1-mutant melanoma 14 ) proposed that U2 spliceosomes with mutant SF3B1 alters the BP choice, which then results in altered 3′SS selection. Validation of this model was performed by mutational analysis of putative BP in a mini-gene constructed from candidate intronic segments. Some limitations of this model include: (1) more widespread 3′SS usage would be expected with altered BP choice (without the enrichment upstream of canonical sites); and (2) recent genome-wide mapping of human BP have shown that a third of exons have multiple potential BP, most of which are within a few base pairs of each other. 26 This strongly suggests that BP usage is highly redundant during splicing and is neither necessary nor sufficient for alternative 3′SS usage.
The model we propose is based on the well-described relationship of secondary structure constraints to splice site choice. Accordingly, cryptic 3′SSs are not used normally during spliceosome scanning in the 5′ → 3′ direction, as they are basepaired within secondary structures rendering them inaccessible. This difference in accessibility holds true regardless of the cryptic 3′SSs being placed upstream or downstream of the canonical 3′ SSs. Our model also accommodates cryptic 3′SSs that are distant (450 nt) from their canonical sites and hence likely to be associated with a different BP. Accordingly, these distal cryptic 3′SSs are likely independent units (with distinct 3′SSs, PPT and BP) but not used normally owing to poor accessibility. They are, however, not in competition with their corresponding canonical 3′ SSs. In mutant SF3B1-containing spliceosomes, these cryptic 3′SSs are recognized and used. Although U2AF assembles at 3′SSs early during the splicing process, final selection of the acceptor site is now thought to occur later by a 5 → 3′ scanning process downstream of the BP. 19, 49 Importantly, our model does not rule out a change in BP choice for cryptic 3′SS selection, rather it suggests that intrinsic features of the cryptic 3′SS (accessibility) determines their selection. Although computational and minigene splicing assays support our model, further validation will come from comprehensive charting of genome-wide BP choice in wild-type and mutant-SF3B1 expressing cells (through direct sequencing of lariat junctions). Cryptic 3′SSs were also not found to be conserved across vertebrate species, suggesting that they are unlikely to have a role in normal physiology. This may also explain recent reports that showed a lack of significant phenotype analogous to the human disease in mice expressing mutant SF3B1, despite having a similar pattern of cryptic 3′SSs across the genome, 50, 51 as transcripts with cryptic 3′SSs in humans are unlikely to have a homologous cryptic 3′SS in mice.
How mutant SF3B1-containing U2 spliceosomes select cryptic 3′SSs within secondary structures is not clear. Proteins interacting with the C-terminal HEAT domains of SF3B1 are not known, but it is reasonable to speculate that the mutation could change its interaction with one or more of factors involved in 3′SS selection. This may include RNA helicases, which are essential for unwinding of both snRNA and target pre-mRNA during splicing. 52 Interestingly, recent descriptions of mutations in DDX41 (a dead box RNA helicase) and splicing anomalies in patients affected by these somatic mutations underscore a direct connection between premRNA secondary structure and splicing in the context of MDS. 53 A separate potential mechanism is based on recently described interaction between SF3B1 and chromatin. 54 Given that splicing is co-transcriptional, rate of transcription dictates how nascent RNA folds into secondary structures. It is hence possible that mutant SF3B1 changes transcription rate such that the second step of splicing is completed before cryptic 3′SSs are sequestered within dynamic secondary structure. Precise details of 3′SS choice in mutant SF3B1 cells will likely emerge out of studies that define the direct targets of SF3B1 binding (such as cross-linking immunoprecipitation sequencing), crystal structure of SF3B1 and complete charting of BPs (lariat sequencing).
Differentially spliced genes are enriched for biological pathways of relevance to MDS and cancer biology. Interestingly, differential expression at the protein level could be demonstrable for alternatively spliced genes such as UBE2I although their transcript levels were not different. Conversely, some genes (such as EGR1 and DLK1) were not aberrantly spliced although differentially expressed at the transcript and protein levels. NMD of aberrantly spliced transcripts has been invoked as a potential mechanism that links splicing factor mutations and disease 11, 55 ; in our analysis, NMD was not clearly demonstrable in differentially expressed genes, including Mitoferrin 1. This suggests that the precise link between aberrant splicing and disease physiology is complex and may not be readily evident from transcriptome analysis for splicing and gene expression.
In summary, our results provide a model for understanding how mutant SF3B1 expression may lead to cryptic 3′SS selection. It forms the basis for further biochemical work that will define how the mutant protein accomplishes recognition of the inaccessible 3′SSs and identify detailed mechanisms of tumorigenesis associated with mutant splicing factor expression.
MATERIALS AND METHODS
Cloning of SF3B1, cell culture, vector construction and viral vector production Native SF3B1 sequences are toxic to E. coli as reported previously. 12 Sequence of human SF3B1 open reading frame was optimized by the inhouse software provided by Genscript (Piscataway, NJ, USA), synthesized and cloned into pUC57 and subsequently cloned to other expression vectors with an N-terminal FLAG-tag. Mutant SF3B1 constructs (for expression of K700E, K666N and K666R) were generated by site-directed mutagenesis as described in Supplementary Methods. Unless otherwise specified, mutant SF3B1 denotes SF3B1 K700E (lysine to glutamic acid substitution at position 700, the most common mutation in MDS) while SF3B1
WT denotes the unmutated wild-type construct. K562 and MEL were grown in RPMI-1640 supplemented with 10% fetal calf serum. 293FT cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% cosmic calf serum (Hyclone, South Logan, UT, USA). K562 cells were used as the experimental model given human CD34+ cell transductions resulted in low (~5%) efficiencies and an inability to expand in culture (likely due to toxicity from enforced expression). A single cistron doxycycline-inducible viral vector model (pInducer 20 or 21 vectors, WT . Canonical 3′SS usage is thus favored. With SF3B1 K700E , these cryptic 3′SS are rendered accessible by an unknown mechanism and is favored during the splicing catalysis, leading to aberrantly spliced products. Supplementary Figures S1A and B) , was used to allow for titration of induced transgene levels by varying concentrations of doxycycline. Inducible lentiviral constructs were made by first cloning the SF3B1 constructs into pENTR4 (Addgene, Cambridge, MA, USA plasmid 17424) vector and transferring to destination vectors (pInducer20 and pInducer 21 (Addgene plasmids 44012 and 46948, respectively 56 )). Lentiviral vectors were prepared by calcium phosphate transfection of 293FT cells with viral plasmid constructs along with helper plasmids pdelta8.92 and pCMV-VSVG as previously described. 57 Viral supernatants were concentrated using PEG6000. Cells were transduced with viral concentrates and selected by either flow sorting for green fluorescent protein expression (pinducer21 transduced cells) or Geneticin (500 μg/ml for 10-14 days). Inducible expression of FLAG-SF3B1 and total SF3B1 were separately determined by western blotting, and the levels were compared ensuring that inducible transgene expression remained in the physiological range ( Supplementary  Figures S1C and D) . Two single-cell clones were identified for each transgene with comparable levels of inducible expression and subsequently studied. Primary analysis described in this manuscript are for SF3B1
WT and SF3B1-K700E induced with doxycycline (referred henceforth as SF3B1
WT and SF3B1 K700E , respectively). Induction was performed for 48 h with 1 μg/ml of doxycycline. For NMD analysis, cells were treated with cycloheximide (100 μg/ml) for 30 min or dimethyl sulfoxide (control).
RNA sequencing and analysis
Total RNA was extracted from approximately five million cultured cells using the RNEasy MINI-Kit. rRNA depletion was performed by RNAseH treatment as previously described. 58 Strand-specific (dUTP protocol) cDNA libraries with barcodes suitable for multiplexed Illumina sequencing were prepared in duplicates for each condition (wild-type uninduced (SF3B1 WT− ), wild-type induced (SF3B1 WT ), K700E or mutant uninduced (SF3B1 K700E − ) and mutant induced (SF3B1 K700E )). Pooled libraries in equimolar ratios (four libraries per lane) were sequenced on the Illumina HiSeq2000 (Illumina, San Diego, CA, USA), 2 ×76 (paired-end) per sample. Paired-end sequencing data of eight MDS patients with SF3B1 mutations and five healthy controls were downloaded from GEO database (GSE63569). 13 Details of informatic analyses, including packages used, and custom scripts generated are in Supplementary Methods. Custom scripts written for the analysis have been deposited at https://github.com/ pillailab under the repository 'SF3B1_Splicing'.
Reverse transcription, PCR and mini-gene splicing assay cDNA was prepared from total RNA depleted of genomic DNA (on-column DNAse treatment) and SuperscriptIII reverse transcriptase (Life Technologies, Carlsbad, CA, USA) using random hexamers. Real-time quantitative PCR was performed using paired oligos and Sybr Fast (KAPA Biosystems, Wilmington, MA, USA) 2 × mastermix on a Bio-rad Laboratories (Hercules, CA, USA) CFX96 real-time PCR cycler. To determine splice isoforms, cDNA was amplified with suitable primers and resolved on 3% Metaphor agarose. Mini-gene splicing assays were performed using constructs cloned in to the RG6 vector 31 (details in Supplementary Methods).
Western blotting and enzyme-linked immunosorbent assay (ELISA)
Protein detection and quantification were accomplished by western blotting analysis using standard reagents and methodology as previously reported. 57 Specific conditions for blocking, primary and secondary antibody binding are described in Supplementary Methods. Immunoreactive bands were visualized using Pierce enhanced chemiluminescence substrate (Life Technologies). ELISA for soluble DLK1 was performed using the DLK1 duo-set ELISA Kit (RnD Biosystems, Minneapolis, MN, USA) per the manufacturer's instruction and read on a Biotek Synergy 2 (Biotek Instruments, Winooski, VT, USA) plate reader.
Data access
Sequencing files generated from this work have been deposited in the GEO under GSE70959.
Statistical considerations
RNA-Seq was performed in duplicates as per the ENCODE guidelines (https://genome.ucsc.edu/ENCODE/experiment_guidelines.html). Detailed statistical analytical parameters for RNA-Seq and splicing are detailed in Supplementary Methods. Individual experiments including PCR, western blottings and ELISA were performed in biological replicates of three. The results of each experiment are reported as the mean of experimental replicates. Error bars represent the s.d. from the mean. If not otherwise indicated, pairwise comparisons were analyzed using the unpaired twosided t-test (GraphPad Prism, GraphPad Software, La Jolla, CA, USA). Pvalueo0.05 was considered significant.
